20-F: iTonic 20-F: Losses surge, cash burn and dilution

iTonic Holdings posted a $5.1m FY25 net loss on higher public company and deal costs, flagged going-concern doubt, and plans a 100m-share private placement at $0.20, implying heavy dilution.

Summary

• FY25 revenue rose 16.7% to $523,031 (FY24: $448,196; FY23: $628,591) as Medical Auxiliary Supplies doubled to $160,181 while FTTPS software was $362,850.
• Gross profit fell to $327,351 with margin compressing to 62.6% (FY24: 85.0%) on higher delivery and customization costs.
• Operating expenses jumped to $5,514,314 (FY24: $1,151,421), driven by G&A of $4,873,326 (+549%) and R&D of $459,135 (+392%).
• Net loss widened to $5,098,384 (FY24: $660,588; FY23: $241,217); loss from operations was $5,186,963.
• Year-end cash and restricted cash dropped to $1,490,129 (FY24: $6,159,823); operating cash outflow was $3,231,427; short-term investments were $1,435,901.
• Auditor included a going-concern emphasis; management disclosed material weaknesses in internal control (U.S. GAAP/SEC expertise, lack of formal risk framework, and broad IT general control gaps).
• Closed 51% acquisition of iTonic Corporation (Nov 25, 2025); recognized goodwill $1,955,683, intangible assets $2,414,357, and deferred tax liabilities $507,015.
• Nasdaq minimum bid price deficiency notice received Oct 20, 2025; shareholders authorized potential share consolidation up to 1:4,000 (Dec 19, 2025).
• Announced a private placement of 100,000,000 Class A shares at $0.20 (Mar 23, 2026) with a six‑month lock‑up, expected to close in April 2026.
• Dual‑class structure concentrates voting control (~94% combined voting power) with the CEO; outstanding shares at 12/31/25: 9,382,000 Class A and 7,668,000 Class B.

Sentiment

Score: 3

Explanation: StockSavvy.ai views the combination of larger losses, cash burn, going-concern emphasis, internal control weaknesses, Nasdaq deficiency, and planned heavy dilution as materially negative.

Positives

• FY25 revenue increased 16.7% to $523,031, with Medical Auxiliary Supplies up 104% to $160,181.
• R&D investment accelerated to $459,135 to enhance AI features and SaaS delivery for FTTPS.
• Closed 51% acquisition of iTonic Corporation to enter U.S. home health tech; recognized identifiable intangibles of $2,414,357.
• Maintained working capital of $3,625,621 at 12/31/25; added $1,435,901 in short-term investments.
• Gross margin remains positive (62.6%) despite mix shift and higher delivery/customization costs.

Negatives

• Net loss surged to $5,098,384 (vs. $660,588 in FY24) as G&A rose to $4,873,326 (public company costs, deal expenses, and $2,945,495 share-based payment).
• Operating cash outflow of $3,231,427 and cash balance decline to $1,490,129 from $6,159,823 indicate elevated burn.
• Gross margin compressed to 62.6% (from 85.0%), reflecting higher costs and mix shift.
• Auditor raised substantial doubt about going concern; management disclosed three material weaknesses in internal control.
• Customer concentration increased (top two customers = 51% of FY25 revenue); supplier concentration (one supplier 54% of purchases in FY25).

Risks

• Going-concern uncertainty due to recurring losses and negative operating cash flows; potential cessation of operations if new capital not secured.
• PRC regulatory, licensing, and cybersecurity uncertainties; reliance on maintaining Class III device production/operation licenses and medical device registration certificate.
• Nasdaq minimum bid price deficiency (Oct 20, 2025) and potential share consolidation authorization (Dec 19, 2025).
• Material weaknesses in internal control over financial reporting (U.S. GAAP/SEC expertise, lack of risk framework, and IT general control deficiencies).
• Customer and supplier concentration; FY25 top two customers accounted for 26% and 25% of revenue; one supplier 54% of purchases.
• Foreign exchange, geopolitics, and China-U.S. trade tensions potentially impacting costs, supply chain, and demand.
• High insider control via Class B shares (20:1 votes) may limit minority shareholder influence and affect governance.
• Potential dilution from announced private placement of 100,000,000 Class A shares at $0.20 with six-month lock-up.

Future Outlook

Management plans to expand internationally (Southeast Asia), invest in R&D (AI recognition in FTTPS, potential surgical robotics), and monetize upgrades and 3D printing-enabled workflows. Funding plans include potential equity and debt financing to sustain operations.

Management Comments

• Intends to fund operations through increased sales and by exploring additional equity and debt financing; inability to secure short-term capital could lead to cessation of operations.
• Believes PRC cybersecurity review is not currently required and does not anticipate collecting personal data of one million users in the foreseeable future.
• Plans to reinitiate Southeast Asia expansion and offer upgrade services for next-generation FTTPS with 3D printing integration.

Industry Context

StockSavvy.ai notes that TPS for radiotherapy is a niche within oncology software. China’s cancer burden underpins demand, but hospital procurement, licensing, and price controls can slow uptake. Large global radiation players (e.g., Varian/Siemens Healthineers, Elekta) dominate external beam; brachytherapy TPS competition is limited but exists in China (six NMPA-approved products). Macro headwinds (China-U.S. trade, cybersecurity/data rules) and hospital budget pressures present ongoing execution risks.

Comparison to Industry Standards

• Revenue scale remains micro-cap vs. established radiotherapy peers (Siemens Healthineers/Varian, Elekta), which report multi‑billion revenue with double‑digit margins and robust service annuities.
• Gross margin (62.6%) trails typical high-70s/80s software-like margins seen in mature TPS vendors, reflecting customization and delivery costs, with limited scale.
• R&D intensity increased but remains small in absolute dollars compared with peer investments in AI planning and automation across major platforms.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal proceedings disclosed.

Related Party Transactions

• Advance to CEO Jianfei Zhang of $16,203 at 12/31/25 used as petty cash for business expenses; fully repaid after period, per disclosure.
• Bank loans guaranteed by directors: RMB 1,000,000 loan on 2025-03-18 guaranteed by Director Pengfei Zhang; prior RMB 810,000 loan guaranteed by CEO Jianfei Zhang and Director Pengfei Zhang (repaid 2025-04-15).

Stakeholder Impact

• Shareholders: significant potential dilution from 100,000,000-share private placement and possible reverse split to maintain Nasdaq listing.
• Employees: increased R&D focus; PRC social insurance and housing fund compliance from July 2024.
• Customers: concentration risk with top two customers contributing 51% of FY25 revenue; product support and licensing continuity are critical.
• Suppliers: dependence on a few vendors (one supplier 54% of FY25 purchases) could affect delivery and costs.
• Creditors: going-concern doubt and negative operating cash flow heighten financing risk.

Next Steps

• Pursue closing of the March/April 2026 private placement to bolster liquidity.
• Address Nasdaq bid price deficiency by April 20, 2026; share consolidation authorization already obtained.
• Remediate internal control material weaknesses (U.S. GAAP/SEC expertise, formal risk framework, IT general controls).
• Integrate iTonic Corporation, realize planned milestone-based earnout structure, and advance U.S. home-health platform.
• Reinitiate Southeast Asia expansion and pursue TPS software upgrades monetization.

Key Dates

Recommendation

Losses escalated, cash balances fell sharply, and the auditor raised going-concern doubt. The announced 100,000,000-share private placement at $0.20 implies severe dilution, while Nasdaq deficiency and internal control weaknesses add execution and listing risk. Despite strategy and acquisitions, risk‑adjusted return appears unfavorable.

Keywords

iTonic Holdings, Beijing Feitian, FTTPS, brachytherapy, treatment planning software, medical devices, Class III medical device, 3D printing, Nasdaq deficiency, going concern, private placement, dual-class shares, iTonic Corporation, Geri-Safe, China healthcare